The session examines mechanisms of action, pharmacokinetic profiles, efficacy and tolerability data, and the impact of stimulant treatment on executive functioning, emotional regulation, quality of life, and long-term outcomes.  It also discusses practical considerations for individualising treatment, managing risks, and supporting patients with coexisting conditions. 

Key topics include:

• The neurochemical basis of ADHD and dysregulated arousal.
• Mechanisms of action of amphetamine and methylphenidate medications.
• Pharmacokinetic differences between stimulant formulations and their clinical relevance.
• Evidence for efficacy, tolerability, and quality-of-life improvements associated with ADHD medication.
• The potential long-term consequences of untreated ADHD and considerations for treatment decision-making.